Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Karolinska University Hospital |
---|---|
Information provided by: | Karolinska University Hospital |
ClinicalTrials.gov Identifier: | NCT00465257 |
The purpose of this study is to assess the efficacy of artesuante + amodiaquine four years after its introduction as first line treatment for uncomplicated childhood malaria in Zanzibar. The hypothesis is that the treatment has a polymerase chain reaction (PCR)adjusted parasitological cure rate of at least 85% 42 days after treatment.
Condition | Intervention | Phase |
---|---|---|
Malaria |
Drug: artesunate + amodiaquine |
Phase IV |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study |
Official Title: | Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction as New Treatment Policy for Uncomplicated Plasmodium Falciparum Malaria in Zanzibar |
Ages Eligible for Study: | 6 Months to 59 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Tanzania, North A District, Zanzibar | |
Kivunge Cottage Hospital | |
Kivunge, North A District, Zanzibar, Tanzania |
Study Director: | Anders Björkman, Professor | Karolinska UH |
Principal Investigator: | Guida Rotlland, MD, MPH | Karolinska UH |
Study ID Numbers: | ACOIII |
Study First Received: | April 23, 2007 |
Last Updated: | May 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00465257 |
Health Authority: | Tanzania: Ministry of Health |
Artesunate Protozoan Infections Amodiaquine |
Parasitic Diseases Malaria Malaria, Falciparum |
Anti-Infective Agents Antimalarials Antiparasitic Agents Antiprotozoal Agents |
Coccidiosis Therapeutic Uses Amebicides Pharmacologic Actions |